144 related articles for article (PubMed ID: 37909093)
1. A New Wave of PI3Kα Inhibitors.
Kearney AL; Vasan N
Cancer Discov; 2023 Nov; 13(11):2313-2315. PubMed ID: 37909093
[TBL] [Abstract][Full Text] [Related]
2. STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts.
Buckbinder L; St Jean DJ; Tieu T; Ladd B; Hilbert B; Wang W; Alltucker JT; Manimala S; Kryukov GV; Brooijmans N; Dowdell G; Jonsson P; Huff M; Guzman-Perez A; Jackson EL; Goncalves MD; Stuart DD
Cancer Discov; 2023 Nov; 13(11):2432-2447. PubMed ID: 37623743
[TBL] [Abstract][Full Text] [Related]
3. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
Varkaris A; Fece de la Cruz F; Martin EE; Norden BL; Chevalier N; Kehlmann AM; Leshchiner I; Barnes H; Ehnstrom S; Stavridi AM; Yuan X; Kim JS; Ellis H; Papatheodoridi A; Gunaydin H; Danysh BP; Parida L; Sanidas I; Ji Y; Lau K; Wulf GM; Bardia A; Spring LM; Isakoff SJ; Lennerz JK; Del Vecchio K; Pierce L; Pazolli E; Getz G; Corcoran RB; Juric D
Cancer Discov; 2024 Feb; 14(2):227-239. PubMed ID: 37916958
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Varkaris A; Pazolli E; Gunaydin H; Wang Q; Pierce L; Boezio AA; Bulku A; DiPietro L; Fridrich C; Frost A; Giordanetto F; Hamilton EP; Harris K; Holliday M; Hunter TL; Iskandar A; Ji Y; Larivée A; LaRochelle JR; Lescarbeau A; Llambi F; Lormil B; Mader MM; Mar BG; Martin I; McLean TH; Michelsen K; Pechersky Y; Puente-Poushnejad E; Raynor K; Rogala D; Samadani R; Schram AM; Shortsleeves K; Swaminathan S; Tajmir S; Tan G; Tang Y; Valverde R; Wehrenberg B; Wilbur J; Williams BR; Zeng H; Zhang H; Walters WP; Wolf BB; Shaw DE; Bergstrom DA; Watters J; Fraser JS; Fortin PD; Kipp DR
Cancer Discov; 2024 Feb; 14(2):240-257. PubMed ID: 37916956
[TBL] [Abstract][Full Text] [Related]
5. Precision Targeting of Mutant PI3Kα in Cancer by Selective Degradation.
Vanhaesebroeck B; Burke JE; Madsen RR
Cancer Discov; 2022 Jan; 12(1):20-22. PubMed ID: 35022207
[No Abstract] [Full Text] [Related]
6. Precision Targeting of Mutant PI3Kα.
Gong GQ; Vanhaesebroeck B
Cancer Discov; 2024 Feb; 14(2):204-207. PubMed ID: 38327193
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
8. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
Menteş M; Karakuzulu BB; Uçar GB; Yandım C
Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959
[TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer.
Auf der Maur P; Trefny MP; Baumann Z; Vulin M; Correia AL; Diepenbruck M; Kramer N; Volkmann K; Preca BT; Ramos P; Leroy C; Eichlisberger T; Buczak K; Zilli F; Okamoto R; Rad R; Jensen MR; Fritsch C; Zippelius A; Stadler MB; Bentires-Alj M
Cell Rep Med; 2023 Apr; 4(4):101002. PubMed ID: 37044095
[TBL] [Abstract][Full Text] [Related]
10. Double
Vasan N; Razavi P; Johnson JL; Shao H; Shah H; Antoine A; Ladewig E; Gorelick A; Lin TY; Toska E; Xu G; Kazmi A; Chang MT; Taylor BS; Dickler MN; Jhaveri K; Chandarlapaty S; Rabadan R; Reznik E; Smith ML; Sebra R; Schimmoller F; Wilson TR; Friedman LS; Cantley LC; Scaltriti M; Baselga J
Science; 2019 Nov; 366(6466):714-723. PubMed ID: 31699932
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of PI3K inhibitors for solid tumour treatment and beyond.
Belli C; Repetto M; Anand S; Porta C; Subbiah V; Curigliano G
Br J Cancer; 2023 Jun; 128(12):2150-2162. PubMed ID: 36914722
[TBL] [Abstract][Full Text] [Related]
12. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
13. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
[TBL] [Abstract][Full Text] [Related]
14. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
Ketcham JM; Harwood SJ; Aranda R; Aloiau AN; Bobek BM; Briere DM; Burns AC; Caddell Haatveit K; Calinisan A; Clarine J; Elliott A; Engstrom LD; Gunn RJ; Ivetac A; Jones B; Kuehler J; Lawson JD; Nguyen N; Parker C; Pearson KE; Rahbaek L; Saechao B; Wang X; Waters A; Waters L; Watkins AH; Olson P; Smith CR; Christensen JG; Marx MA
J Med Chem; 2024 Mar; 67(6):4936-4949. PubMed ID: 38477582
[TBL] [Abstract][Full Text] [Related]
16. The PI3Kα Inhibitor Alpelisib Has Activity in
Cancer Discov; 2018 Apr; 8(4):OF7. PubMed ID: 29453241
[TBL] [Abstract][Full Text] [Related]
17. Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Smith AE; Chan S; Wang Z; McCloskey A; Reilly Q; Wang JZ; Patel HV; Koshizuka K; Soifer HS; Kessler L; Dayoub A; Villaflor V; Adkins DR; Bruce JY; Ho AL; Perez CA; Hanna GJ; Gascó Hernández A; Saunders A; Dale S; Gutkind JS; Burrows F; Malik S
Cancer Res; 2023 Oct; 83(19):3252-3263. PubMed ID: 37339176
[TBL] [Abstract][Full Text] [Related]
18. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
[TBL] [Abstract][Full Text] [Related]
19. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
[TBL] [Abstract][Full Text] [Related]
20. Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
Hanan EJ; Braun MG; Heald RA; MacLeod C; Chan C; Clausen S; Edgar KA; Eigenbrot C; Elliott R; Endres N; Friedman LS; Gogol E; Gu XH; Thibodeau RH; Jackson PS; Kiefer JR; Knight JD; Nannini M; Narukulla R; Pace A; Pang J; Purkey HE; Salphati L; Sampath D; Schmidt S; Sideris S; Song K; Sujatha-Bhaskar S; Ultsch M; Wallweber H; Xin J; Yeap S; Young A; Zhong Y; Staben ST
J Med Chem; 2022 Dec; 65(24):16589-16621. PubMed ID: 36455032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
